Growth response, near-adult height, and patterns of growth and puberty in patients with noonan syndrome treated with growth hormone.

Context: Noonan syndrome (NS) is a heterogeneous genetic disorder characterized by short stature.

Setting: The National Cooperative Growth Study (NCGS), a postmarketing observational study of recombinant human GH (rhGH)-treated children, includes a large cohort of children with NS.

Patients: We studied NCGS-enrolled prepubertal and pubertal children with NS.

Salutary effects of combining early very low-dose systemic estradiol with growth hormone therapy in girls with Turner syndrome.

Context: Optimizing pubertal estrogen replacement in girls with Turner syndrome is important.

Objective: The study objective was to test the hypotheses that physiological estradiol replacement administered early with GH will preserve height potential as much as if administered late and that it will bring about a greater height gain than standard oral estrogen therapy combined with GH.

Design: The study was randomized to early or late estrogen treatment; follow-up was at 3.

Septo-optic dysplasia/optic nerve hypoplasia: data from the National Cooperative Growth Study (NCGS).

We analyzed data from 65 children with septo-optic dysplasia (SOD) referred for evaluation and followed in the National Cooperative Growth Study (NCGS) Substudy 8 and from 758 children treated with growth hormone (GH) and followed in the NCGS core study. Compared to other children referred for evaluation of short stature, children with SOD were younger (mean age 3.7 +/- 3.